## THAT WHICH IS CLAIMED:

- A method of treating a traumatic central nervous system injury, said
  method comprising administering to a patient in need thereof a therapeutically effective
  amount of a composition comprising allopregnanolone.
  - 2. The method of claim 1, wherein said injury is a traumatic brain injury.
- 3. The method of claim 2, wherein said traumatic brain injury results from a blunt force contusion.
  - 4. The method of claim 1, wherein said method reduces edema in the patient following said traumatic CNS injury.
- The method of claim 1, wherein said method reduces the inflammatory response in the patient following said traumatic CNS injury.
  - 6. The method of claim 1, wherein said method reduces neuronal cell death in the patient following said traumatic CNS injury.
  - 7. The method of claim 1, wherein said allopregnanolone is administered in at least one dosage of about 1µg/kg to about 50 mg/kg of body weight.
- 8. The method of claim 7, wherein said allopregnanolone is administered in at least one dosage of about 4 mg/kg of body weight.
  - 9. The method of claim 7, wherein at least one dosage of said allopregnanolone is administered about 0.5 to about 100 hours following the traumatic CNS injury.

30

20

- 10. The method of claim 7, wherein the first dose of the allopregnanolone is administered about 1 hour following the traumatic CNS injury, and a subsequent allopregnanolone dose is administered about 6 hours following the injury.
- The method of claim 7, wherein the first dose of the allopregnanolone is administered about 1 hour following the traumatic brain injury, a second allopregnanolone dosage is administered about 6 hours following the injury, and subsequent allopregnanolone dosages are administered in 24 hour intervals.
- 10 12. The method of claim 1, wherein said allopregnanolone is administered by intraperitoneal, subcutaneous, intravenous or intracerebroventricular administration or any combination thereof.
- 13. The method of claim 1, wherein said allopregnanolone is administered in a pharmaceutically acceptable carrier.
  - 14. The method of claim 13, wherein said carrier is cyclodextrin.
- 15. The method of claim 1, wherein said composition further comprises at least one other neurotrophic agent.
  - 16. A method of decreasing neurodegeneration on a population of cells in a subject following a traumatic injury to the central nervous system, said method comprising administering to a patient in need thereof a therapeutically effective dose of allopregnanolone, wherein said dose produces a neuroprotective effect in the patient.
  - 17. The method of claim 16, wherein said traumatic CNS injury is a traumatic brain injury.
- 30 18. The method of claim 17, wherein the neurodegeneration is associated with cerebral edema.

Atty. Dkt. No.: <u>07157/239838</u> (5543-17)

25

- 19. The method of claim 17, wherein the neurodegeneration is associated with a blunt force contusion.
- 5 20. The method of claim 17, wherein the neurodegeneration is associated with an inflammatory response.

Atty. Dkt. No.: <u>07157/239838</u> (5543-17)